DurAVR™

A New Class of TAVR

Single piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve.

Share and Option Schemes of Arrangement and Extraordinary General Meeting

ANNUAL GENERAL MEETING

Anteris Technologies CEO, Wayne Paterson presents at the Annual General Meeting held on the 29th May 2024 in Sydney.


POST-AGM INTERVIEW

Watch an exclusive post-AGM interview with Anteris CEO, Wayne Paterson, as he discusses key highlights from the meeting, our latest achievements and future plans with Juliette Saly from Ausbiz.


LIVE IN THE CATH LAB

Watch Anteris Technologies CEO, Wayne Paterson, connect live to the Cath Lab in Tbilisi, Georgia for an update on the DurAVR™ THV First In Human study with implanting physicians.


EUROPCR 2024 PHYSICIAN PANEL INTERVIEW

Hear the discussion from Drs Nicolas Van Mieghem, Christopher Meduri, and Azeem Latib on the biomimetic design of the DurAVR™ THV and its impact on hemodynamics and blood flow dynamics.


INVEST IN ANTERIS (ASX: AVR)

We drive awareness and adoption of our ADAPT® technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.

Anteris Technologies Invest AVR ASX

LATEST ANTERIS NEWS

LATEST ANTERIS NEWS

US EFS CLINICAL EVIDENCE

Stay informed with the latest clinical data on DurAVR™ from the US EFS.

DurAVR™: A New Class of TAVR data release at TCT 2023

TVT 2023 DATA PRESENTATION

DurAVR™ THV First-In-Human Presentation with Updated Results

DurAVR™ THV First-In-Human Presentation with Updated Results

ANNUAL GENERAL MEETING

Anteris' Annual General Meeting was held on the 29th of May 2024. 

AGM Details for Anteris Technologies